All In Biotech

Drug Trial Radar · NCT04015024

A Clinical Study of SKLB1028 Capsule in the Treatment of Recurrence/Refractory AML Patients

Phase IIa Clinical Study of SKLB1028 Capsule in the Treatment of FLT3 Mutation Recurrence / Refractory AML Patients

Last checked: Nov 19, 2026Latest source record: Jul 16, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

30

Planned (sponsor's estimate)

Start

Jul 2019

Primary completion

Apr 2021

Study completion Jun 2021

Sponsor

Sponsor type
Industry
First posted
Jul 10, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Single group
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Patients will receive oral SKLB1028 for 28 days as a course of treatment, and then to evaluate the side effects,tolerability and best dose for treating relapsed or refractory acute myeloid leukemia With FLT3 Mutations.

Conditions

  • Acute Myeloid Leukemia

Interventions

  • SKLB1028 150mg bidDrug

    150mg oral administration twice a day

  • SKLB1028 200mg bidDrug

    200mg oral administration twice a day

  • SKLB1028 300mg qdDrug

    300mg oral administration once a day

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Total remission rate (ORR)Time frame: Evaluation at the end of each cycle(a cycle is 28 days) of administration and at the end of the study (assessed up to approximately 24 months)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • West China Hospital,Sichuan University

    Chengdu, Sichuan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.